Millennium Management’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.7M | Buy |
93,646
+90,166
| +2,591% | +$9.41M | ﹤0.01% | 2031 |
|
|
2025
Q4 | $364K | Sell |
3,480
-23,394
| -87% | -$2M | ﹤0.01% | 5140 |
|
|
2025
Q3 | $1.68M | Sell |
26,874
-288,115
| -91% | -$12.8M | ﹤0.01% | 4209 |
|
|
2025
Q2 | $7.1M | Buy |
314,989
+45,152
| +17% | +$1.06M | ﹤0.01% | 2618 |
|
|
2025
Q1 | $7.55M | Buy |
+269,837
| New | +$5.2M | ﹤0.01% | 2461 |
|
|
2024
Q2 | – | Sell |
-2,647
| Closed | -$38.8K | – | 6666 |
|
|
2024
Q1 | $38.8K | Buy |
2,647
+563
| +27% | +$7.84K | ﹤0.01% | 5724 |
|
|
2023
Q4 | $30.3K | Sell |
2,084
-734
| -26% | -$13.4K | ﹤0.01% | 5569 |
|
|
2023
Q3 | $67.2K | Buy |
+2,818
| New | +$60.6K | ﹤0.01% | 5426 |
|
|
2023
Q2 | – | Sell |
-998
| Closed | -$78K | – | 6800 |
|
|
2023
Q1 | $78K | Sell |
998
-5,938
| -86% | -$688K | ﹤0.01% | 5504 |
|
|
2022
Q4 | $577K | Buy |
6,936
+5,006
| +259% | +$402K | ﹤0.01% | 4633 |
|
|
2022
Q3 | $178K | Sell |
1,930
-1,433
| -43% | -$185K | ﹤0.01% | 5724 |
|
|
2022
Q2 | $503K | Sell |
3,363
-5,536
| -62% | -$1.01M | ﹤0.01% | 4951 |
|
|
2022
Q1 | $2.16M | Sell |
8,899
-6,446
| -42% | -$1.69M | ﹤0.01% | 3803 |
|
|
2021
Q4 | $4.64M | Sell |
15,345
-10,241
| -40% | -$3.28M | ﹤0.01% | 2975 |
|
|
2021
Q3 | $10.6M | Sell |
25,586
-11,322
| -31% | -$3.94M | 0.01% | 1982 |
|
|
2021
Q2 | $11.3M | Buy |
+36,908
| New | +$8.09M | 0.01% | 1745 |
|
|
2021
Q1 | – | Sell |
-1,173
| Closed | -$235K | – | 6593 |
|
|
2020
Q4 | $235K | Buy |
1,173
+210
| +22% | +$43.7K | ﹤0.01% | 4719 |
|
|
2020
Q3 | $159 | Sell |
963
-123
| -11% | -$28K | ﹤0.01% | 4128 |
|
|
2020
Q2 | $269K | Buy |
+1,086
| New | +$254K | ﹤0.01% | 3720 |
|
|
2020
Q1 | – | Sell |
-137
| Closed | -$40K | – | 4611 |
|
|
2019
Q4 | $40K | Sell |
137
-325
| -70% | -$90.1K | ﹤0.01% | 4112 |
|
|
2019
Q3 | $126K | Sell |
462
-14,706
| -97% | -$5.69M | ﹤0.01% | 3911 |
|
|
2019
Q2 | $5.7M | Buy |
15,168
+8,128
| +115% | +$2.42M | 0.01% | 1672 |
|
|
2019
Q1 | $1.89M | Sell |
7,040
-4,455
| -39% | -$1.06M | ﹤0.01% | 2447 |
|
|
2018
Q4 | $2.45M | Sell |
11,495
-9,797
| -46% | -$3.04M | ﹤0.01% | 2074 |
|
|
2018
Q3 | $9.54M | Buy |
21,292
+7,774
| +58% | +$3.38M | 0.01% | 1358 |
|
|
2018
Q2 | $5.48M | Sell |
13,518
-9,283
| -41% | -$4.42M | 0.01% | 1756 |
|
|
2018
Q1 | $12.4M | Buy |
22,801
+14,054
| +161% | +$8.7M | 0.02% | 1189 |
|
|
2017
Q4 | $5.28M | Buy |
8,747
+3,208
| +58% | +$1.49M | 0.01% | 1716 |
|
|
2017
Q3 | $2.55M | Buy |
5,539
+2,585
| +88% | +$1.1M | ﹤0.01% | 2036 |
|
|
2017
Q2 | $1.2M | Buy |
+2,954
| New | +$863K | ﹤0.01% | 2358 |
|
|
2016
Q4 | – | Sell |
-228
| Closed | -$33K | – | 3815 |
|
|
2016
Q3 | $33K | Buy |
228
+64
| +39% | +$8.51K | ﹤0.01% | 3201 |
|
|
2016
Q2 | $21K | Sell |
164
-581
| -78% | -$89K | ﹤0.01% | 3103 |
|
|
2016
Q1 | $113K | Sell |
745
-1,247
| -63% | -$175K | ﹤0.01% | 3065 |
|
|
2015
Q4 | $365K | Buy |
+1,992
| New | +$334K | ﹤0.01% | 2814 |
|
Other funds holding PVLA
SCM
FLAM
BI
FLSM
VCM
Millennium Management's PVLA Position: Q1 2026 in Review
Millennium Management increased its Palvella Therapeutics (PVLA) stake by 2,591% in Q1 2026, buying an estimated $9.41M and bringing the position to 93,646 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2031.
Millennium Management first reported a position in PVLA in Q4 2015 and has held it in 34 quarters since. The position peaked at $12.4M in Q1 2018. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.
- Millennium Management held 93,646 shares of Palvella Therapeutics worth $11.7M as of Q1 2026.
- Millennium Management bought 90,166 Palvella Therapeutics shares in Q1 2026, an estimated $9.41M.
- Palvella Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2031 holding.
- Millennium Management first reported a position in Palvella Therapeutics in Q4 2015 and has held it in 34 quarters since.
- Millennium Management's Palvella Therapeutics position peaked at $12.4M in Q1 2018.
- 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.